Nature Search

Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

Lindsay B. Kilburn
Dong-Anh Khuong-Quang
Karsten Nysom
Amendments and CorrectionsOpen Access16 Apr 2025
Nature Medicine

Volume: 31, P: 2454
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

In a phase 2 trial, the oral type II RAF inhibitor tovorafenib exhibited an overall response rate of 67% in patients with BRAF-altered relapsed/refractory pediatric low-grade glioma.

Lindsay B. Kilburn
Dong-Anh Khuong-Quang
Karsten Nysom
ResearchOpen Access17 Nov 2023
Nature Medicine

Volume: 30, P: 207-217
A multi-omic dissection of super-enhancer driven oncogenic gene expression programs in ovarian cancer

Super-enhancers and their associated transcription factor networks have been shown to influence ovarian cancer biology. Here, based on an integrated set of genomic and epigenomic datasets, the authors identify clinically relevant super-enhancers amplified in ovarian cancer patients and functionally validate their activity.

Michael R. Kelly
Kamila Wisniewska
Hector L. Franco
ResearchOpen Access22 Jul 2022
Nature Communications

Volume: 13, P: 1-22
K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas

Comprehensive genomic profiling of human H3K27M mutant diffuse midline gliomas, combining single-cell RNA sequencing and ATAC sequencing with bulk ChIP sequencing and other data, proposes distinct oligodendrocyte populations as potential cells of origin.

Selin Jessa
Abdulshakour Mohammadnia
Claudia L. Kleinman
Research05 Dec 2022
Nature Genetics

Volume: 54, P: 1865-1880
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

Lindsay B. Kilburn
Dong-Anh Khuong-Quang
Karsten Nysom
Amendments and CorrectionsOpen Access11 Mar 2024
Nature Medicine

Volume: 30, P: 1500
Epigenetic and transcriptional profiling of triple negative breast cancer

Andrea A. Perreault
Danielle M. Sprunger
Bryan J. Venters
ResearchOpen Access05 Mar 2019
Scientific Data

Volume: 6, P: 1-9
Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype–phenotype correlation

Magdalena Koczkowska
Tom Callens
Ludwine M. Messiaen
ResearchOpen Access07 Sept 2018
Genetics in Medicine

Volume: 21, P: 867-876
ChIP-seq and ChIP-exo profiling of Pol II, H2A.Z, and H3K4me3 in human K562 cells

Zenab F. Mchaourab
Andrea A. Perreault
Bryan J. Venters
ResearchOpen Access06 Mar 2018
Scientific Data

Volume: 5, P: 1-8
The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation

A new mechanism by which acute myeloid leukaemia patients become resistant to Ara-C and a newer treatment, ribavirin, is uncovered; these drugs can be glucuronidated and thereby inactivated by members of the UDP glucuronosyltransferase family of enzymes activated through GLI1 signalling.

Hiba Ahmad Zahreddine
Biljana Culjkovic-Kraljacic
Katherine L. B. Borden
Research28 May 2014
Nature

Volume: 511, P: 90-93
Correction: Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype–phenotype correlation

Magdalena Koczkowska
Tom Callens
Ludwine M. Messiaen
Amendments and Corrections02 Oct 2018
Genetics in Medicine

Volume: 21, P: 764-765

Search

Filter By:

Search

Quick links